Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook

64Cu-DOTATATE

  • You have access
    64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection
    Mathias Loft, Esben A. Carlsen, Camilla B. Johnbeck, Helle H. Johannesen, Tina Binderup, Andreas Pfeifer, Jann Mortensen, Peter Oturai, Annika Loft, Anne K. Berthelsen, Seppo W. Langer, Ulrich Knigge and Andreas Kjaer
    Journal of Nuclear Medicine January 1, 2021, 62 (1) 73-80; DOI: https://doi.org/10.2967/jnumed.120.244509
  • You have access
    64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor–Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial
    Ebrahim S. Delpassand, David Ranganathan, Nilesh Wagh, Afshin Shafie, Ayman Gaber, Ali Abbasi, Andreas Kjaer, Izabela Tworowska and Rodolfo Núñez
    Journal of Nuclear Medicine June 1, 2020, 61 (6) 890-896; DOI: https://doi.org/10.2967/jnumed.119.236091
  • You have access
    Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors
    Camilla B. Johnbeck, Ulrich Knigge, Annika Loft, Anne K. Berthelsen, Jann Mortensen, Peter Oturai, Seppo W. Langer, Dennis R. Elema and Andreas Kjaer
    Journal of Nuclear Medicine March 1, 2017, 58 (3) 451-457; DOI: https://doi.org/10.2967/jnumed.116.180430
  • You have access
    64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients
    Andreas Pfeifer, Ulrich Knigge, Tina Binderup, Jann Mortensen, Peter Oturai, Annika Loft, Anne Kiil Berthelsen, Seppo W. Langer, Palle Rasmussen, Dennis Elema, Eric von Benzon, Liselotte Højgaard and Andreas Kjaer
    Journal of Nuclear Medicine June 1, 2015, 56 (6) 847-854; DOI: https://doi.org/10.2967/jnumed.115.156539
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire